Cargando…

Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications

Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Laudicella, Riccardo, Albano, Domenico, Annunziata, Salvatore, Calabrò, Diletta, Argiroffi, Giovanni, Abenavoli, Elisabetta, Linguanti, Flavia, Vento, Antonio, Bruno, Antonio, Alongi, Pierpaolo, Bauckneht, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826849/
https://www.ncbi.nlm.nih.gov/pubmed/31546734
http://dx.doi.org/10.3390/cancers11101412
_version_ 1783465188626792448
author Laudicella, Riccardo
Albano, Domenico
Annunziata, Salvatore
Calabrò, Diletta
Argiroffi, Giovanni
Abenavoli, Elisabetta
Linguanti, Flavia
Albano, Domenico
Vento, Antonio
Bruno, Antonio
Alongi, Pierpaolo
Bauckneht, Matteo
author_facet Laudicella, Riccardo
Albano, Domenico
Annunziata, Salvatore
Calabrò, Diletta
Argiroffi, Giovanni
Abenavoli, Elisabetta
Linguanti, Flavia
Albano, Domenico
Vento, Antonio
Bruno, Antonio
Alongi, Pierpaolo
Bauckneht, Matteo
author_sort Laudicella, Riccardo
collection PubMed
description Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supporting the use of radiolabelled somatostatin receptor analogues (such as dota-peptides) to provide molecular imaging of meningiomas might at least partially overcome these limitations. Moreover, their potential therapeutic usage might enrich the current clinical offering for these patients. Starting from the strengths and weaknesses of structural and functional neuroimaging in meningiomas, in the present article we systematically reviewed the published studies regarding the use of radiolabelled dota-peptides in surgery and radiotherapy planning, in the restaging of treated patients, as well as in peptide-receptor radionuclide therapy of meningioma.
format Online
Article
Text
id pubmed-6826849
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68268492019-11-18 Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications Laudicella, Riccardo Albano, Domenico Annunziata, Salvatore Calabrò, Diletta Argiroffi, Giovanni Abenavoli, Elisabetta Linguanti, Flavia Albano, Domenico Vento, Antonio Bruno, Antonio Alongi, Pierpaolo Bauckneht, Matteo Cancers (Basel) Review Meningiomas account for approximately 30% of all new diagnoses of intracranial masses. The 2016 World Health Organization’s (WHO) classification currently represents the clinical standard for meningioma’s grading and prognostic stratification. However, watchful waiting is frequently the chosen treatment option, although this means the absence of a certain histological diagnosis. Consequently, MRI (or less frequently CT) brain imaging currently represents the unique available tool to define diagnosis, grading, and treatment planning in many cases. Nonetheless, these neuroimaging modalities show some limitations, particularly in the evaluation of skull base lesions. The emerging evidence supporting the use of radiolabelled somatostatin receptor analogues (such as dota-peptides) to provide molecular imaging of meningiomas might at least partially overcome these limitations. Moreover, their potential therapeutic usage might enrich the current clinical offering for these patients. Starting from the strengths and weaknesses of structural and functional neuroimaging in meningiomas, in the present article we systematically reviewed the published studies regarding the use of radiolabelled dota-peptides in surgery and radiotherapy planning, in the restaging of treated patients, as well as in peptide-receptor radionuclide therapy of meningioma. MDPI 2019-09-22 /pmc/articles/PMC6826849/ /pubmed/31546734 http://dx.doi.org/10.3390/cancers11101412 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Laudicella, Riccardo
Albano, Domenico
Annunziata, Salvatore
Calabrò, Diletta
Argiroffi, Giovanni
Abenavoli, Elisabetta
Linguanti, Flavia
Albano, Domenico
Vento, Antonio
Bruno, Antonio
Alongi, Pierpaolo
Bauckneht, Matteo
Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
title Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
title_full Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
title_fullStr Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
title_full_unstemmed Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
title_short Theragnostic Use of Radiolabelled Dota-Peptides in Meningioma: From Clinical Demand to Future Applications
title_sort theragnostic use of radiolabelled dota-peptides in meningioma: from clinical demand to future applications
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826849/
https://www.ncbi.nlm.nih.gov/pubmed/31546734
http://dx.doi.org/10.3390/cancers11101412
work_keys_str_mv AT laudicellariccardo theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT albanodomenico theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT annunziatasalvatore theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT calabrodiletta theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT argiroffigiovanni theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT abenavolielisabetta theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT linguantiflavia theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT albanodomenico theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT ventoantonio theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT brunoantonio theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT alongipierpaolo theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications
AT baucknehtmatteo theragnosticuseofradiolabelleddotapeptidesinmeningiomafromclinicaldemandtofutureapplications